Alpha- and beta-adrenergic receptor (AR) protein expression is associated with poor clinical outcome in XXXX : an immunohistochemical study.

@entity1 @entity0 @entity588 @entity7514 @entity5 @entity470 @entity12251 @entity7273 @entity876 @entity4205 @entity3 @entity1758 @entity6881 @entity1722
@entity0 mortality is frequently associated with @entity3 . @entity3 models have shown adrenoceptor (AR) stimulation induces cell migration which is inhibited by adrenoceptor antagonist drugs. We investigated adrenoceptor protein expression in clinical @entity0 and its association with disease progression and prognosis. Immunohistochemistry on tissue microarrays was used to characterise a1b, a2c and b(2)2 adrenoceptor protein expression in operable @entity0 . Associations with @entity5 -relevant biological markers and clinical outcome were statistically assessed. Strong a1b expression occurred in large high grade (P < 0.0001), @entity1722 + (P < 0.0001) or basal-like ( @entity4205 , P = 0.0005; @entity6881 , P = 0.0001; @entity470 , P = 0.003) @entity5 , showing increased proliferation ( @entity1758 , P = 0.002), decreased apoptosis ( @entity588 , P < 0.0001) and poor NPI membership (P = 0.001). a1b expression correlated with poor @entity5 -specific survival (LR = 7.628, P = 0.022) and @entity5 recurrence (LR = 6.128, P = 0.047). Strong a2c was over-expressed in high grade (P = 0.007), @entity7514 + (P = 0.002) and @entity12251 + (P < 0.0001) @entity5 with borderline increase in @entity470 , @entity876 and @entity1758 proteins, and inverse association with hormonal ( @entity7273 , P = 0.002) phenotype. In contrast, strong b(2) expression occurred in small-size, luminal-like (ER+, P < 0.001) @entity5 of low grade (P < 0.001) and lymph node stage (P = 0.027) that showed poor prognosis when hormonal treatment was withheld. Adrenoceptors were not found to be independent predictors of clinical outcome. Alpha1b and a2c AR is over-expressed in basal-like @entity0 of poor prognosis. Strong b(2) adrenoceptor expression is seen in @entity1 with a luminal (ER+) @entity5 phenotype and good prognosis, due to benefits derived from hormonal therapy. These findings suggest a possible role for targeted therapy using adrenoceptor antagonists.
